Immediate Evaluation for Pregnancy-Specific Liver Disease
This 28-week primigravida with persistently elevated ALT and AST requires urgent measurement of serum bile acids and comprehensive evaluation to exclude life-threatening conditions including intrahepatic cholestasis of pregnancy (ICP), preeclampsia/HELLP syndrome, and acute fatty liver of pregnancy (AFLP).
Critical First Steps
Measure Serum Bile Acids Immediately
- Total serum bile acids (TSBA) are the single most important test to identify pregnancies at risk of stillbirth 1
- If TSBA >10 μmol/L with elevated transaminases, this confirms ICP 2
- TSBA >100 μmol/L carries markedly increased stillbirth risk after 35 weeks 1
Exclude Life-Threatening Conditions
Simultaneously evaluate for:
- Preeclampsia/HELLP syndrome: Check blood pressure, platelet count, hemolysis markers, and proteinuria 1
- AFLP: Assess for coagulopathy (PT/INR), hypoglycemia, renal dysfunction, and altered mental status 3
- These conditions require immediate delivery planning and intensive monitoring
Diagnostic Algorithm Based on Results
If TSBA Elevated (>10 μmol/L) = Intrahepatic Cholestasis of Pregnancy
Risk Stratification by Bile Acid Level:
TSBA <40 μmol/L:
TSBA 40-100 μmol/L:
TSBA >100 μmol/L:
If TSBA Normal but ALT/AST Persistently Elevated
Exclude other hepatic pathology:
- Viral hepatitis: HCV, HBV, HEV serology 1
- Autoimmune hepatitis: ANA, SMA, anti-mitochondrial antibody 1
- Biliary obstruction: Liver ultrasound 1
- Continue monitoring TSBA every 2 weeks until 32 weeks, then weekly—bile acids may rise later in pregnancy 1
Management Priorities
UDCA Treatment
- Reduces spontaneous preterm birth and may protect against stillbirth in ICP with TSBA >40 μmol/L 1
- Modest effect on maternal pruritus 1
- Continue until delivery, then stop or taper over 2-4 weeks if symptoms persist 1
Monitoring Intensity
- Weekly TSBA and LFT from 32 weeks gestation for confirmed ICP 1
- Bile acids can continue rising with advancing gestation—this is why frequent monitoring is critical 1
- Recent evidence shows ALT combined with other markers can predict adverse outcomes 1, 4
Delivery Timing
This is the definitive treatment and must be individualized to bile acid levels:
- The risk-benefit calculation balances prematurity complications against stillbirth risk
- TSBA >100 μmol/L: Deliver at 35-36 weeks 2, 1
- TSBA 40-100 μmol/L: Deliver at 36-37 weeks 2
- TSBA <40 μmol/L: May deliver at term (39 weeks) 1
Critical Pitfalls to Avoid
- Do not delay bile acid measurement—transaminases alone cannot risk-stratify ICP 1
- Do not assume stable disease—bile acids frequently rise in third trimester, requiring weekly monitoring 1
- Do not miss HELLP/preeclampsia—these require immediate delivery regardless of gestational age 2, 1
- Do not continue pregnancy beyond 36 weeks with TSBA >100 μmol/L—stillbirth risk increases dramatically after 35 weeks 1